 |
|
|
| |
Clinical Characteristics of Patients Who Developed HCC While Receiving Tenofovir Disoproxil Fumarate (TDF) Up to 336 Weeks of Therapy
|
| |
| |
Reported by Jules Levin
APASL June 6-10 2013 Singapore
W. Ray Kim1, Rohit Loomba2, Selim Gurel3, John Flaherty4, Eduardo B. Martins4, Leland J. Yee4, Phillip Dinh4, Maria Buti5, Patrick Marcellin6
1Mayo Clinic, Rochester, MN, USA; 2University of California at San Diego, San Diego, CA, USA; 3University of Uludag, Bursa, Turkey;
4Gilead Sciences, Inc., Foster City, CA, USA; 5Hospital General Universitari Vall d'Hebron, Barcelona, Spain; 6Hopital Beaujon, University of Paris, Clichy, France
|
| |
|
|
|
|
|
